KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Deferred Taxes (2022 - 2025)

Neogenomics' Deferred Taxes history spans 4 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 73.14% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $3.4 million, up 9.41%, while the annual FY2025 figure was $3.4 million, 9.41% up from the prior year.
  • Deferred Taxes reached $2.7 million in Q4 2025 per NEO's latest filing, up from -$869000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $5.7 million in Q2 2022 to a low of -$869000.0 in Q3 2025.
  • Average Deferred Taxes over 4 years is $2.1 million, with a median of $2.3 million recorded in 2023.
  • The largest YoY upside for Deferred Taxes was 109.05% in 2025 against a maximum downside of 456.15% in 2025.
  • A 4-year view of Deferred Taxes shows it stood at $3.3 million in 2022, then plummeted by 45.34% to $1.8 million in 2023, then fell by 14.18% to $1.6 million in 2024, then surged by 73.14% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Deferred Taxes are $2.7 million (Q4 2025), -$869000.0 (Q3 2025), and $993000.0 (Q2 2025).